Barbara K Kemp-Harper Selected Research

Therapeutics

1/2023	A high-sucrose diet exacerbates the left ventricular phenotype in a high fat-fed streptozotocin rat model of diabetic cardiomyopathy.
1/2021	Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO•) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation.
1/2021	Simultaneous targeting of oxidative stress and fibrosis reverses cardiomyopathy-induced ventricular remodelling and dysfunction.
1/2020	Nitroxyl: A Novel Strategy to Circumvent Diabetes Associated Impairments in Nitric Oxide Signaling.
1/2020	Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis.
1/2019	Inflammasomes: a novel therapeutic target in pulmonary hypertension?
1/2017	The opposing roles of NO and oxidative stress in cardiovascular disease.
8/2013	HNO/cGMP-dependent antihypertrophic actions of isopropylamine-NONOate in neonatal rat cardiomyocytes: potential therapeutic advantages of HNO over NO.
5/2011	Chronic administration of the HNO donor Angeli's salt does not lead to tolerance, cross-tolerance, or endothelial dysfunction: comparison with GTN and DEA/NO.
12/2009	Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Barbara K Kemp-Harper Research Topics

Disease

11	Hypertension (High Blood Pressure) 11/2021 - 08/2007
9	Inflammation (Inflammations) 04/2023 - 01/2017
8	Fibrosis (Cirrhosis) 04/2023 - 09/2015
7	Heart Failure 01/2023 - 04/2007
6	Cardiovascular Diseases (Cardiovascular Disease) 11/2023 - 05/2011
6	Hypertrophy 04/2023 - 01/2012
3	Cardiomyopathies (Cardiomyopathy) 04/2023 - 01/2021
3	Diabetes Mellitus 01/2020 - 05/2015
3	Cardiomegaly (Heart Hypertrophy) 08/2013 - 01/2012
2	Atherosclerosis 06/2023 - 07/2007
2	Diabetic Cardiomyopathies 01/2023 - 05/2015
2	Left Ventricular Dysfunction 01/2023 - 05/2015
2	Stroke (Strokes) 01/2023 - 01/2011
2	Pulmonary Hypertension 11/2021 - 01/2019
2	Hyperglycemia 01/2020 - 01/2020
2	Hypercholesterolemia 10/2013 - 10/2011
2	Vascular Diseases (Vascular Disease) 10/2011 - 07/2007
1	Atherosclerotic Plaque (Atheroma) 06/2023
1	Microvascular Rarefaction 04/2023
1	Infarction (Infarctions) 01/2023
1	Type 2 Diabetes Mellitus (MODY) 01/2023
1	Hypoxia (Hypoxemia) 01/2022
1	Kidney Diseases (Kidney Disease) 11/2021
1	Renal Hypertension 11/2021
1	Cicatrix (Scar) 01/2020
1	Myocardial Infarction 01/2020
1	Body Weight (Weight, Body) 01/2020
1	Hypotension (Low Blood Pressure) 12/2019
1	Thrombosis (Thrombus) 01/2019
1	Albuminuria 01/2019
1	Chronic Disease (Chronic Diseases) 01/2019
1	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2011
1	Alzheimer Disease (Alzheimer's Disease) 01/2011
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 12/2009
1	Disease Progression 12/2009

Drug/Important Bio-Agent (IBA)

10	nitroxylIBA 01/2020 - 04/2007
8	Superoxides (Superoxide)IBA 01/2021 - 07/2007
7	Nitric Oxide (Nitrogen Monoxide)FDA Link 06/2023 - 08/2007
5	InflammasomesIBA 11/2021 - 01/2017
4	Angiotensin IIIBA 01/2017 - 01/2011
3	CytokinesIBA 11/2023 - 01/2019
3	CollagenIBA 06/2023 - 01/2017
3	salicylhydroxamic acid (SHAM)IBA 01/2023 - 01/2020
3	Streptozocin (Streptozotocin)FDA Link 01/2023 - 05/2015
3	Desoxycorticosterone Acetate (DOCA)FDA Link 11/2021 - 01/2017
3	Acetates (Acetic Acid Esters)FDA Link 11/2021 - 05/2015
3	SaltsIBA 11/2021 - 01/2017
3	Interleukin-18 (Interleukin 18)IBA 11/2021 - 01/2019
3	Vasodilator Agents (Vasodilators)IBA 04/2017 - 08/2007
3	1-isopropyldiazen-1-ium-1,2-diolateIBA 09/2013 - 10/2011
2	NitratesIBA 06/2023 - 05/2011
2	Isoproterenol (Isoprenaline)FDA LinkGeneric 04/2023 - 01/2021
2	RelaxinIBA 04/2023 - 01/2023
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2023 - 01/2021
2	Desoxycorticosterone (Deoxycorticosterone)IBA 11/2021 - 01/2017
2	VenomsIBA 12/2019 - 01/2019
2	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 01/2019 - 01/2017
2	Antihypertensive Agents (Antihypertensives)IBA 01/2017 - 09/2013
2	AnionsIBA 01/2016 - 04/2007
2	Soluble Guanylyl CyclaseIBA 01/2012 - 01/2012
2	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2012 - 07/2007
1	Interleukin-4 (Interleukin 4)IBA 11/2023
1	Interleukin-13IBA 11/2023
1	Apolipoproteins E (ApoE)IBA 06/2023
1	LipidsIBA 06/2023
1	Perindopril FDA LinkGeneric 04/2023
1	relaxin receptorsIBA 01/2023
1	Hormones (Hormone)IBA 01/2023
1	Peptide Receptors (Peptide Receptor)IBA 01/2023
1	ThioninsIBA 01/2023
1	Sucrose (Saccharose)IBA 01/2023
1	MonocrotalineIBA 01/2022
1	ReninIBA 11/2021
1	Peroxynitrous Acid (Peroxynitrite)IBA 01/2021
1	AntioxidantsIBA 01/2021
1	Hydroxyl RadicalIBA 01/2021
1	Acetylcysteine (Siran)FDA LinkGeneric 01/2021
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 01/2021
1	Therapeutic UsesIBA 01/2021
1	Blood Glucose (Blood Sugar)IBA 01/2020
1	C.I. direct red 80IBA 01/2019
1	InterleukinsIBA 01/2019
1	AnticoagulantsIBA 01/2019
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2017
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2017
1	Drinking WaterIBA 01/2017
1	ElastinIBA 09/2015
1	Chemokine ReceptorsIBA 09/2015
1	sodium bisulfide (NaHS)IBA 01/2015
1	ApolipoproteinsIBA 10/2013
1	1,1-diethyl-2-hydroxy-2-nitrosohydrazineIBA 09/2013
1	BAY 58-2667IBA 01/2012
1	LigandsIBA 01/2012
1	Nitric Oxide Synthase (NO Synthase)IBA 08/2007

Therapy/Procedure

10	Therapeutics 01/2023 - 12/2009
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 11/2021
1	Drug Therapy (Chemotherapy) 01/2012